# A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

> **NCT05770609** · PHASE2 · COMPLETED · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 53 (actual)

## Conditions studied

- Mild to Moderate Ulcerative Colitis

## Interventions

- **DRUG:** SPH3127 Tablets with Dose A
- **DRUG:** SPH3127 Tablets with Dose B
- **DRUG:** SPH3127 Tablets placebo

## Key facts

- **NCT ID:** NCT05770609
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-19
- **Primary completion:** 2024-09-13
- **Final completion:** 2024-09-13
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05770609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05770609, "A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05770609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*